Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
GH Research ( (GHRS) ) has provided an announcement.
GH Research announced successful results from Phase 2a proof-of-concept trials for their GH001 treatment in postpartum depression and bipolar II disorder, meeting primary endpoints with significant reductions in depression scores. Additionally, the company completed FDA-requested toxicology studies with no respiratory toxicity findings, clearing a path to address an IND hold. Upcoming milestones include a response to the FDA in mid-2025 and top-line data from a Phase 2b trial in TRD expected in Q1 2025.
More about GH Research
GH Research PLC is a clinical-stage biopharmaceutical company focused on transforming the treatment of psychiatric and neurological disorders, with an initial focus on developing proprietary mebufotenin therapies for treatment-resistant depression (TRD).
YTD Price Performance: 13.53%
Average Trading Volume: 70,992
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $467.2M
See more insights into GHRS stock on TipRanks’ Stock Analysis page.
